Navigation Links
NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
Date:4/2/2013

AMES, Iowa, April 2, 2013 /PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the initiation of a double-blind, randomized, placebo-controlled Phase 2 clinical study of its first IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, indoximod, in patients with metastatic breast cancer. The Phase 2 clinical study will evaluate indoximod as a new approach to treating cancer by administering this novel IDO pathway inhibitor, designed to counteract a key mechanism by which tumors evade immune-mediated destruction, in combination with a conventional cytotoxin, docetaxel. This Phase 2 clinical study follows the successful Phase 1b dose-escalation study of indoximod in patients with advanced solid tumors in which a favorable safety profile and promising early signs of activity were observed. Indoximod is the most advanced product candidate to enter clinical trials based on NewLink's proprietary IDO pathway inhibitor platform for small-molecule, orally bioavailable cancer immunotherapies.

"There is significant unmet need for new approaches that may offer more effective treatment options for patients with metastatic breast cancer, a leading cause of death in women in the United States," said Hatem Soliman , MD, a medical oncologist specializing in breast cancer in The Center for Women's Oncology at Moffitt Cancer Center and the principal investigator for this study. "Indoximod has demonstrated promising safety, pharmacokinetic and biologic activity in earlier clinical studies and we look forward to increasing our understanding of its potential in metastatic breast cancer with this robust Phase 2 study designed to evaluate the activity of indoximod in combination with a co
'/>"/>

SOURCE NewLink Genetics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Epigenetics: Changing the Way We Think about DNA
2. Research and Markets: Cytogenetics - Technologies, Markets and Companies - 2013
3. Plunketts Biotech & Genetics Industry Almanac 2013: Biotech & Genetics Industry Market Research, Statistics, Trends & Leading Companies
4. Plunketts Biotech & Genetics Industry Trends & Statistics 2013: A Summary Version of Plunketts Biotech & Genetics Industry Almanac 2013
5. GeneTex Launches New Antibody Against Phosphorylated Histone H3 for Epigenetics Research
6. The American College of Obstetricians and Gynecologists Committee on Genetics and the Society for Maternal-Fetal Medicine Publications Committee Recommend Noninvasive Prenatal Testing for Fetal Aneuploidy
7. Response Genetics, Inc. to Offer ROS1 Testing for Lung Cancer
8. Epigenetics Holds Key to Healthier Future
9. Response Genetics, Inc. Announces Second Quarter Financial Results
10. Genetics Policy Institute (GPI) Collaborates on Second Midwest Conference on Stem Cell Biology and Therapy, Oct. 5-7 at Oakland University
11. Applied Genetics Initiates Commercial Operation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today ... have approved the resolutions relating to: (i) a ... units at a price of $2.67 per unit ... of one common share and 0.075358 common share ... million; and (ii) the amendment to Resverlogix,s articles ...
(Date:6/30/2015)... 30, 2015  Today, Americord Registry, one of the fastest ... Horne , a partner at Kirkland & Ellis LLP, as ... Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   "We are thrilled ... says Martin Smithmyer , CEO of Americord. "He brings ... that will assist Americord,s growth and vision." ...
(Date:6/30/2015)... , ... June 30, 2015 , ... The maximum number ... Cryo-Cell’s currently outstanding common shares (including shares of unvested restricted stock). On June 29, ... last sale price of Cryo-Cell’s shares reported on the OTCBB was $2.29 per share. ...
(Date:6/30/2015)... 30, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... medicine company focused on the development of autologous ... its Phase 1/2 clinical trial of RCT-01, being ... tendinosis, has been enrolled and their tissue biopsy ... RCT-01 is comprised of non-bulbar dermal sheath (NBDS) ...
Breaking Biology Technology:Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3Americord Registry Announces Andrew Horne as Advisory Board Member 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4
... SUNNYVALE, Calif., Feb. 6 Cepheid (Nasdaq:,CPHD) will ... full year,2007 after the markets close on Thursday, ... a live conference call and webcast that afternoon ... ), John Bishop, Chief Executive Officer, and ...
... SGXP ) announced today that the Company will be presenting ... -- 10th Annual BIO CEO & Investor Conference: Wednesday, February ... Time at the Waldorf=Astoria, New York City. -- Roth 20th ... at 11:30 AM Pacific Standard Time at the Ritz ...
... A new generation of sensors for detecting explosives and ... of radiation known as,T-rays, published today (3 February) in ... T-rays, electromagnetic waves in the far,infrared part of the ... visible light, can be guided along the surface of ...
Cached Biology Technology:Cepheid Schedules Teleconference and Webcast for 2007 Fourth Quarter and Full Year Results 2'T-ray' breakthrough signals next generation of security sensors 2
(Date:6/30/2015)... -- Genisphere announced Tom Bliss ... develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss comes ... of the last 25 years in leadership positions at ... & Johnson. Tom started his career in Investment Banking, ... He graduated from Dartmouth College with a BA in ...
(Date:6/25/2015)... June 25, 2015 According ... Type (Swipe & Area), Technology, Material (Optical Prism, ... Commercial Security & Others) & Geography - Global ... the said market is expected to reach $14,500.07 ... Browse 76 market Tables and ...
(Date:6/24/2015)... The biologics safety testing market is growing ... market include growth of the pharmaceutical and biological industries ... the years, the number of drug approvals in North ... FDA approved 225 drug applications and Health Canada approved ... accounted for 3,822 of the pharmaceutical and ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... SALT LAKE CITY, Nov. 15, 2012 ActiveCare, ... and diabetes management solutions, announced a dramatic decrease in ... relationship with Caprock HealthPlans. ActiveCare,s revolutionary health monitoring and ... specialists has lead to a healthier Caprock. By collecting ...
... available in Spanish . , Artificial logs that ... made from a perhaps surprising source: grass clippings. ... chemist Syed H. Imam and his colleagues have shown that lawn ... fire logs that burn brightly and evenly. The same formula can ...
... streams begins to occur at the initial stages of urban ... study found that streams are more sensitive to development than ... as fragile organisms, and yet that is exactly what the ... said USGS Director Marcia McNutt. "Streams are more than water, ...
Cached Biology News:Diabetes Management Provider ActiveCare Announces Cost Savings Of Over $4,000 Per Year Per Diabetic Member 2Fire logs made from lawn clippings offer earth-friendly option 2Streams show signs of degradation at earliest stages of urban development 2
... is a premium quality recombinant form of ... is suitable for a wide range of ... and reproducible performance, each preparation is extensively ... assays. NovaTaq DNA Polymerase possesses an integral ...
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse monoclonal antibody raised against a full length recombinant LDB3. NCBI Entrez Gene ID = LDB3...
...
Biology Products: